Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commit Lozenge ads

This article was originally published in The Tan Sheet

Executive Summary

TV spots for OTC smoking cessation lozenge airing now on major networks, GSK says. Designed by Arnold McGrath Worldwide, ads feature different angles of a lone cigarette against a simple background. "This thing you carry with you everywhere, this thing you obsess about and face ridicule for, this thing you're not sure you'll ever be able to quit, may have just met its match," a voiceover states, before detailing recommended use of Commit. TV spots will be complemented by 1Web site, newspaper ads in publications such as USA Today. Commit nicotine polacrilex lozenge debuted late last month, features "time to first cigarette" dosage selection tool (2"The Tan Sheet" Nov. 4, 2002, p. 3)...

You may also be interested in...



GSK Commit Lozenge Phase IV Studies On Contraindications, AEs Planned

GlaxoSmithKline's Phase IV obligations for its Commit nicotine polacrilex lozenge include a study of consumers who are contraindicated for use of the OTC smoking cessation drug due to underlying health conditions, FDA's Oct. 31 approval letter states

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Topics

UsernamePublicRestriction

Register

PS094897

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel